|
Name |
Sulochrin
|
Molecular Formula | C17H16O7 | |
IUPAC Name* |
methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxybenzoate
|
|
SMILES |
CC1=CC(=C(C(=C1)O)C(=O)C2=C(C=C(C=C2OC)O)C(=O)OC)O
|
|
InChI |
InChI=1S/C17H16O7/c1-8-4-11(19)15(12(20)5-8)16(21)14-10(17(22)24-3)6-9(18)7-13(14)23-2/h4-7,18-20H,1-3H3
|
|
InChIKey |
YJRLSCDUYLRBIZ-UHFFFAOYSA-N
|
|
Synonyms |
Sulochrin; 519-57-3; Methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxybenzoate; CHEBI:16159; 8NA53C271Z; Benzoic acid, 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxy-, methyl ester; m-Anisic acid, 5-hydroxy-2-(4-methyl-.gamma.-resorcyloyl)-, methyl ester; m-Anisic acid, 5-hydroxy-2-(4-methyl-gamma-resorcyloyl)-, methyl ester; UNII-8NA53C271Z; Sulochrin_120096; MLS000863634; CHEMBL61133; SCHEMBL233392; MEGxm0_000192; ACon0_000926; ACon1_000208; DTXSID80199860; HMS2268H19; ZINC895263; Sulochrin, >=98% (HPLC), solid; NCGC00180780-01; SMR000440729; HY-105713; CS-0026511; C00495; BRD-K94458351-001-01-5; Q27098405; methyl 2-(2,6-dihydroxy-4-methyl-benzoyl)-5-hydroxy-3-methoxy-benzoate; Methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxybenzoate #
|
|
CAS | 519-57-3 | |
PubChem CID | 160505 | |
ChEMBL ID | CHEMBL61133 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 332.3 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 113.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 24 | QED Weighted: | 0.583 |
Caco-2 Permeability: | -5.007 | MDCK Permeability: | 0.00001110 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.013 |
Human Intestinal Absorption (HIA): | 0.093 | 20% Bioavailability (F20%): | 0.093 |
30% Bioavailability (F30%): | 0.78 |
Blood-Brain-Barrier Penetration (BBB): | 0.049 | Plasma Protein Binding (PPB): | 97.63% |
Volume Distribution (VD): | 0.504 | Fu: | 4.13% |
CYP1A2-inhibitor: | 0.956 | CYP1A2-substrate: | 0.883 |
CYP2C19-inhibitor: | 0.324 | CYP2C19-substrate: | 0.062 |
CYP2C9-inhibitor: | 0.68 | CYP2C9-substrate: | 0.853 |
CYP2D6-inhibitor: | 0.561 | CYP2D6-substrate: | 0.354 |
CYP3A4-inhibitor: | 0.705 | CYP3A4-substrate: | 0.149 |
Clearance (CL): | 13.727 | Half-life (T1/2): | 0.754 |
hERG Blockers: | 0.031 | Human Hepatotoxicity (H-HT): | 0.045 |
Drug-inuced Liver Injury (DILI): | 0.94 | AMES Toxicity: | 0.656 |
Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.852 |
Skin Sensitization: | 0.197 | Carcinogencity: | 0.022 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.936 |
Respiratory Toxicity: | 0.119 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002468 | 0.795 | D07MGA | 0.344 | ||||
ENC005978 | 0.795 | D06GCK | 0.304 | ||||
ENC005979 | 0.795 | D04AIT | 0.284 | ||||
ENC002375 | 0.778 | D0Y7PG | 0.269 | ||||
ENC002109 | 0.757 | D0K8KX | 0.265 | ||||
ENC006012 | 0.730 | D00KRE | 0.265 | ||||
ENC002683 | 0.730 | D00WVW | 0.265 | ||||
ENC004806 | 0.724 | D04OSE | 0.260 | ||||
ENC001490 | 0.679 | D0E6OC | 0.260 | ||||
ENC002461 | 0.662 | D0AZ8C | 0.256 |